Apremilast

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1402 publications

DMARDs and gout therapy in patients with chronic arthritis and end-stage renal disease: a descriptive guide.

DMARDs and gout therapy in patients with chronic arthritis and end-stage renal disease: a descriptive guide.

Journal: Acta clinica Belgica

Published: April 05, 2026

PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.

PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.

Journal: Expert opinion on pharmacotherapy

Published: March 14, 2026

Apremilast as an Adjuvant in Refractory Reactive Arthritis: A Retrospective Observational Study.

Apremilast as an Adjuvant in Refractory Reactive Arthritis: A Retrospective Observational Study.

Journal: Cureus

Published: March 09, 2026

On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies.

On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies.

Journal: The Journal of dermatological treatment

Published: February 24, 2026

Drugs for atopic dermatitis.

Drugs for atopic dermatitis.

Journal: The Medical letter on drugs and therapeutics

Published: February 23, 2026

PDE4 Inhibitor Apremilast Rebalances Inflammatory Responses to Pseudomonas aeruginosa Infection in CF Rats.

PDE4 Inhibitor Apremilast Rebalances Inflammatory Responses to Pseudomonas aeruginosa Infection in CF Rats.

Journal: bioRxiv : the preprint server for biology

Published: February 23, 2026

3-Aminoisoquinolines inhibit selectively phosphodiesterase 4B in KRAS-mutated colorectal cancer cell lines in-vitro and in-vivo.

3-Aminoisoquinolines inhibit selectively phosphodiesterase 4B in KRAS-mutated colorectal cancer cell lines in-vitro and in-vivo.

Journal: Anti-cancer drugs

Published: February 21, 2026

Successful Long-Term Management of Psoriatic Arthritis With Apremilast Following Multiple Myeloma Diagnosis During Etanercept Therapy: A 20-Month Follow-up.

Successful Long-Term Management of Psoriatic Arthritis With Apremilast Following Multiple Myeloma Diagnosis During Etanercept Therapy: A 20-Month Follow-up.

Journal: The Annals of pharmacotherapy

Published: February 09, 2026

From Convenience to Clinical Efficacy: Selective TYK2 Inhibition in Psoriasis and the Evolving Role of Next-Generation Oral Targeted Therapies.

From Convenience to Clinical Efficacy: Selective TYK2 Inhibition in Psoriasis and the Evolving Role of Next-Generation Oral Targeted Therapies.

Journal: Pharmaceutics

Published: February 08, 2026

PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology.

PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology.

Journal: The Journal of clinical and aesthetic dermatology

Published: February 06, 2026

Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database.

Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database.

Journal: Journal of clinical medicine

Published: February 01, 2026

Pharmacomicrobiomics in Psoriasis: Microbiome-Drug Interactions Across Systemic Treatments.

Pharmacomicrobiomics in Psoriasis: Microbiome-Drug Interactions Across Systemic Treatments.

Journal: Life (Basel, Switzerland)

Published: January 24, 2026

Showing 1-12 of 1,402

Last Updated: 04/28/2026